DE69920497D1 - Liponsaürederivate und deren verwendung bei der behandlung von krankheiten - Google Patents

Liponsaürederivate und deren verwendung bei der behandlung von krankheiten

Info

Publication number
DE69920497D1
DE69920497D1 DE69920497T DE69920497T DE69920497D1 DE 69920497 D1 DE69920497 D1 DE 69920497D1 DE 69920497 T DE69920497 T DE 69920497T DE 69920497 T DE69920497 T DE 69920497T DE 69920497 D1 DE69920497 D1 DE 69920497D1
Authority
DE
Germany
Prior art keywords
acid derivatives
treating diseases
liponic acid
diseased cells
liponic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920497T
Other languages
English (en)
Other versions
DE69920497T2 (de
Inventor
M Bingham
Zuzana Zachar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of DE69920497D1 publication Critical patent/DE69920497D1/de
Application granted granted Critical
Publication of DE69920497T2 publication Critical patent/DE69920497T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE69920497T 1998-10-26 1999-10-26 Liponsaürederivate und deren verwendung bei der behandlung von krankheiten Expired - Lifetime DE69920497T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10562898P 1998-10-26 1998-10-26
US105628P 1998-10-26
PCT/US1999/025140 WO2000024734A1 (en) 1998-10-26 1999-10-26 Lipoic acid derivatives and their use in treatment of disease

Publications (2)

Publication Number Publication Date
DE69920497D1 true DE69920497D1 (de) 2004-10-28
DE69920497T2 DE69920497T2 (de) 2006-02-09

Family

ID=22306916

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69920497T Expired - Lifetime DE69920497T2 (de) 1998-10-26 1999-10-26 Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE69941800T Expired - Lifetime DE69941800D1 (de) 1998-10-26 1999-10-26 Salze von Liponsaürederivaten und deren Verwendung bei der Behandlung von Krankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69941800T Expired - Lifetime DE69941800D1 (de) 1998-10-26 1999-10-26 Salze von Liponsaürederivaten und deren Verwendung bei der Behandlung von Krankheiten

Country Status (12)

Country Link
US (2) US6331559B1 (de)
EP (3) EP2145883A1 (de)
JP (2) JP4728481B2 (de)
AT (2) ATE451362T1 (de)
AU (1) AU774362B2 (de)
BR (1) BR9914789A (de)
CA (1) CA2348998C (de)
DE (2) DE69920497T2 (de)
ES (2) ES2340488T3 (de)
IL (2) IL142824A0 (de)
MX (1) MXPA01004152A (de)
WO (1) WO2000024734A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
JP2002530396A (ja) * 1998-11-25 2002-09-17 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム スカベンジャー化合物
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2162586B1 (es) * 1999-11-25 2002-07-01 Moraleda Manuel Gomez Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
JP2004514716A (ja) 2000-11-30 2004-05-20 ビーエーエスエフ　アクチェンゲゼルシャフト リポ酸およびジヒドロリポ酸の調製方法
US7700080B2 (en) * 2001-03-19 2010-04-20 Senju Pharmaceutical Co., Ltd. Method of suppressing melanin production by metal chelates of lipoyl amino acid derivatives
US6936641B2 (en) * 2002-06-25 2005-08-30 Johnson & Johnson Vision Care, Inc. Macromer forming catalysts
US7038071B2 (en) * 2002-07-16 2006-05-02 Sonus Pharmaceuticals, Inc. Platinum compounds
KR100973450B1 (ko) 2002-09-13 2010-08-02 유겐가이샤 오가 리서치 멜라닌 소거제
JP2006519229A (ja) 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
US20040248982A1 (en) * 2003-06-09 2004-12-09 Dyer Gordon Wayne Use of compounds for the inhibition of proteins and UV protection
US8071645B2 (en) * 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
US7129368B2 (en) * 2004-03-15 2006-10-31 Sonus Pharmaceuticals, Inc. Platinum carboxylate anticancer compounds
US7582418B2 (en) * 2004-11-03 2009-09-01 Albion Laboratories, Inc. Antimicrobial chelates
US20100184710A1 (en) * 2005-04-28 2010-07-22 The Regents Of The University Of Colorado Therapeutic Bifunctional Compounds
US8329753B2 (en) * 2005-05-02 2012-12-11 The Regents Of The University Of Colorado Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition
US20070225354A1 (en) * 2006-03-21 2007-09-27 Eric Marchewitz Use of dihydrolipoamide for enhancing physical performance
BRPI0810439B1 (pt) * 2007-04-18 2021-06-29 Cornerstone Pharmaceuticals, Inc. Formulações farmacêuticas contendo derivados de ácido lipóico
MX2009011316A (es) * 2007-04-18 2010-03-26 Cornerstone Pharmaceuticals Inc Derivados del acido lipoico.
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
KR20110004846A (ko) * 2008-03-04 2011-01-14 로버트 쇼어 효소의 구조, 활성 및/또는 발현 정도의 조절
SG189714A1 (en) 2008-04-01 2013-05-31 Antipodean Pharmaceuticals Inc Compositions and methods for skin care
MX2010010867A (es) * 2008-04-04 2011-05-25 Robert Shorr Composicion farmaceutica.
CA2730773A1 (en) 2008-07-14 2010-01-21 Martha Karen Newell Methods and products for treating proliferative diseases
WO2010019225A1 (en) * 2008-08-15 2010-02-18 Robert Shorr Pharmaceutical composition
EP2350274B1 (de) 2008-10-21 2019-01-23 The General Hospital Corporation Zelltransplantation
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
WO2010062381A1 (en) * 2008-11-28 2010-06-03 Robert Shorr Organelle-specific drug delivery
JP2012510511A (ja) * 2008-12-01 2012-05-10 インヴアスク セラピューテイックス インコーポレイテッド レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用
CN101787013B (zh) * 2009-01-22 2013-04-24 杭州民生药业有限公司 硫辛酰胺系列衍生物、制备方法及所述衍生物的制药用途
WO2010110887A1 (en) * 2009-03-24 2010-09-30 Robert Shorr Fatty acids
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
WO2011046583A1 (en) * 2009-09-11 2011-04-21 Robert Shorr Pharmaceutical exploitation of oxidative stress in transformed cells
FR2959668B1 (fr) * 2010-05-05 2012-07-13 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011146635A1 (en) * 2010-05-21 2011-11-24 North Texas Medical Associates Malignant neoplasm treatment protocol
KR101809301B1 (ko) 2010-08-06 2018-01-18 더 제너럴 하스피털 코포레이션 두잉 비즈니스 애즈 매사츄세츠 제너럴 하스피털 세포 처리 시스템 및 장치
EP2934542A4 (de) * 2012-12-19 2016-08-10 Robert Shorr Pharmazeutische verbindungen
US9605012B2 (en) * 2013-01-17 2017-03-28 Garnett Mckeen Laboratory, Inc. Palladium-ruthenium-zinc-organo complexes and methods for their use in the treatment of inflammatory diseases
AU2014398233B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
ES2819175T3 (es) 2014-06-19 2021-04-15 Rafael Pharmaceuticals Inc Compuestos farmacéuticos
US10052305B2 (en) 2015-10-07 2018-08-21 Buck Institute For Research On Aging Lipoic acid and derivatives thereof for the treatment of cystinuria
CN117263907B (zh) * 2023-09-23 2026-01-27 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362916C (de) 1921-08-13 1922-11-02 Eduard Duerr Abnehmbares Mikrometer fuer Schublehren
GB758897A (en) 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US2853497A (en) 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2872458A (en) * 1954-12-30 1959-02-03 Merck & Co Inc Addition product of a metal hydrocarbon mercaptide with an alpha-halogamma-butyrolactone
JPS57123107A (en) 1981-01-26 1982-07-31 Pola Chem Ind Inc Cosmetic
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
DE3626116A1 (de) 1986-08-01 1988-02-11 Karl Thiel Thermostatische regeleinrichtung fuer heizungen bzw. heizaggregate
DE3629116A1 (de) * 1986-08-27 1988-03-10 Asta Pharma Ag Verfahren zur herstellung enantiomerenreiner r-(+)-(alpha)-liponsaeure und s-(-)-(alpha)-liponsaeure (thioctsaeure) sowie nonen- beziehungsweise mesylderivate als zwischenprodukte hierfuer
DE3900649A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
JPH03193758A (ja) * 1989-12-25 1991-08-23 Nisshin Oil Mills Ltd:The 新規γ―アミノ酪酸誘導体
EP0530446B1 (de) * 1991-07-05 1998-01-28 ASTA Medica Aktiengesellschaft Verwendung von Schwefel enthaltenden Carbonsäuren zur Bekämpfung von pathophysiologisch bedingten Erregungsstörungen
DE4137773A1 (de) * 1991-11-16 1993-05-19 Degussa Herstellung und verwendung von salzen der reinen enantiomere der (alpha)-liponsaeure
WO1994006794A1 (en) 1992-09-24 1994-03-31 National Institutes Of Health Aralkyl diazabicycloalkane derivatives for cns disorders
DE4310142A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE4447599C2 (de) * 1994-11-08 1998-02-26 Asta Medica Ag Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponsäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung von Hörstörungen
DE19601787C1 (de) 1996-01-19 1997-07-24 Asta Medica Ag Herstellung und Verwendung von Salzen der 6,8-Bis(amidiniumthio)-octansäure
ATE310738T1 (de) 1996-07-05 2005-12-15 Us Gov Health & Human Serv Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
EP0855396A1 (de) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Metabolite von Thioctsäure und deren Verwendung
JP4777489B2 (ja) * 1997-03-31 2011-09-21 ザ チルドレンズ メディカル センター コーポレーション アポトーシス性酵素を不活性化するためのニトロシル化
AU728488B2 (en) * 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
JPH11124379A (ja) * 1997-10-17 1999-05-11 Ss Pharmaceut Co Ltd ジチオリリデンアセトアミド誘導体
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
EA036432B1 (ru) 2016-02-05 2020-11-10 Эа Фарма Ко., Лтд. Производные сульфонамида и содержащие их фармацевтические композиции

Also Published As

Publication number Publication date
JP2002528446A (ja) 2002-09-03
ES2340488T3 (es) 2010-06-04
CA2348998C (en) 2012-03-06
DE69941800D1 (de) 2010-01-21
US6951887B2 (en) 2005-10-04
MXPA01004152A (es) 2002-06-04
AU774362B2 (en) 2004-06-24
JP5727721B2 (ja) 2015-06-03
ATE451362T1 (de) 2009-12-15
EP1124820A1 (de) 2001-08-22
CA2348998A1 (en) 2000-05-04
EP1486495B1 (de) 2009-12-09
ATE277034T1 (de) 2004-10-15
US6331559B1 (en) 2001-12-18
ES2229790T3 (es) 2005-04-16
BR9914789A (pt) 2001-10-02
US20020107234A1 (en) 2002-08-08
EP2145883A1 (de) 2010-01-20
IL142824A0 (en) 2002-03-10
DE69920497T2 (de) 2006-02-09
JP2010248203A (ja) 2010-11-04
IL142824A (en) 2010-11-30
WO2000024734A1 (en) 2000-05-04
EP1124820B1 (de) 2004-09-22
JP4728481B2 (ja) 2011-07-20
AU1324600A (en) 2000-05-15
EP1486495A1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
DE69920497D1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE3871751D1 (de) Gelbildende organosiloxanzusammensetzungen und deren verwendung.
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE275608T1 (de) Behandlung von mineralfüllstoffen mit phosphaten, diese füllstoffe und deren verwendung
DE3852374D1 (de) Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE69004081D1 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE198895T1 (de) Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
DE60013859D1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE59813690D1 (de) Substituierte heterocyclen und deren verwendung in arzneimitteln
ATE208384T1 (de) Verwendung von ascorbyl-gamma-linolenat und von ascorbyl-dihomo-gamma-linolenat zur behandlung von asthma, krebs, kardiovaskulären und inflammatorischen erkrankungen
DE69841041D1 (de) Stent beschichtet mit dna
ATE395433T1 (de) Screeningverfahren für geeignete wirkstoffe
ATE259818T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
AT384234B (de) Verfahren zur behandlung von zeolithen und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition